Condition
Major Liver Resection
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Terminated2
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06770803Not ApplicableNot Yet Recruiting
High Versus Low Pneumoperitoneum PressUre for Parenchymal Transection in Minimally Invasive Major Liver Surgery
NCT03179995Phase 2TerminatedPrimary
Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy
NCT02555293Phase 2Terminated
Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection
Showing all 3 trials